Levi & Korsinsky announces it has commenced an investigation of Gilead Sciences Inc. (“Gilead Sciences” or the “Company”) (NASDAQ:GILD) concerning possible violations of federal securities laws.

On May 6, 2016, Gilead acknowledged receipt of a subpoena from the U.S. Attorney’s Office for the District of Massachusetts in February 2016. According to the Company, the subpoena requested documents related to the Company’s “support of 501(c)(3) organizations that provide financial assistance to patients, and for our HCV products, documents concerning our provision of financial assistance to patients.” Then on May 27, 2016, Bloomberg reported that Gilead is one of three major drugmakers to disclose in a recent SEC filing the receipt of a subpoena as part of this expanding federal investigation. To obtain additional information about the investigation, go to:

http://zlk.9nl.com/gilead-sciences-gild

or contact Eduard Korsinsky, Esq. either via email at ek@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.